Frontiers in Molecular Biosciences (May 2023)
Targeted transcriptomic analysis of pancreatic adenocarcinoma in EUS-FNA samples by NanoString technology
- L. Pedrosa,
- I. K. Araujo,
- I. K. Araujo,
- M. Cuatrecasas,
- M. Cuatrecasas,
- M. Cuatrecasas,
- G. Soy,
- G. Soy,
- S. López,
- J. Maurel,
- J. Maurel,
- J. Maurel,
- J. Maurel,
- C. Sánchez-Montes,
- C. Montironi,
- C. Montironi,
- T. Saurí,
- T. Saurí,
- T. Saurí,
- O. Sendino,
- O. Sendino,
- F. M. Pérez,
- F. Ausania,
- F. Ausania,
- F. Ausania,
- G. Fernández-Esparrach,
- G. Fernández-Esparrach,
- G. Fernández-Esparrach,
- G. Fernández-Esparrach,
- F. M. Espósito,
- F. M. Espósito,
- E. C. Vaquero,
- E. C. Vaquero,
- E. C. Vaquero,
- A. Ginès,
- A. Ginès,
- A. Ginès,
- A. Ginès
Affiliations
- L. Pedrosa
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- I. K. Araujo
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- I. K. Araujo
- Endoscopy Unit, Gastroenterology Department, ICMDM, Hospital Clínic, Barcelona, Spain
- M. Cuatrecasas
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- M. Cuatrecasas
- Pathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clínic, Barcelona, Spain
- M. Cuatrecasas
- Facultat de Medicina i Ciències de la Salut, University of Barcelona (UB), Barcelona, Spain
- G. Soy
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- G. Soy
- Endoscopy Unit, Gastroenterology Department, ICMDM, Hospital Clínic, Barcelona, Spain
- S. López
- Pathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clínic, Barcelona, Spain
- J. Maurel
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- J. Maurel
- Facultat de Medicina i Ciències de la Salut, University of Barcelona (UB), Barcelona, Spain
- J. Maurel
- Medical Oncology Department, Translational Genomics and Targeted Therapies in Solid Tumors, ICMHO, Hospital Clínic, Barcelona, Spain
- J. Maurel
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
- C. Sánchez-Montes
- Endoscopy Unit, Gastroenterology Department, ICMDM, Hospital Clínic, Barcelona, Spain
- C. Montironi
- Pathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clínic, Barcelona, Spain
- C. Montironi
- Molecular Biology Core, CDB, Hospital Clinic, Barcelona, Spain
- T. Saurí
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- T. Saurí
- Facultat de Medicina i Ciències de la Salut, University of Barcelona (UB), Barcelona, Spain
- T. Saurí
- Medical Oncology Department, Translational Genomics and Targeted Therapies in Solid Tumors, ICMHO, Hospital Clínic, Barcelona, Spain
- O. Sendino
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- O. Sendino
- Endoscopy Unit, Gastroenterology Department, ICMDM, Hospital Clínic, Barcelona, Spain
- F. M. Pérez
- Pathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clínic, Barcelona, Spain
- F. Ausania
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- F. Ausania
- Facultat de Medicina i Ciències de la Salut, University of Barcelona (UB), Barcelona, Spain
- F. Ausania
- Department of General and Digestive Surgery, ICMDM, Hospital Clínic, Barcelona, Spain
- G. Fernández-Esparrach
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- G. Fernández-Esparrach
- Endoscopy Unit, Gastroenterology Department, ICMDM, Hospital Clínic, Barcelona, Spain
- G. Fernández-Esparrach
- Facultat de Medicina i Ciències de la Salut, University of Barcelona (UB), Barcelona, Spain
- G. Fernández-Esparrach
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
- F. M. Espósito
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- F. M. Espósito
- Medical Oncology Department, Translational Genomics and Targeted Therapies in Solid Tumors, ICMHO, Hospital Clínic, Barcelona, Spain
- E. C. Vaquero
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- E. C. Vaquero
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
- E. C. Vaquero
- Gastroenterology Department, ICMDM, Hospital Clínic, Barcelona, Spain
- A. Ginès
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
- A. Ginès
- Endoscopy Unit, Gastroenterology Department, ICMDM, Hospital Clínic, Barcelona, Spain
- A. Ginès
- Facultat de Medicina i Ciències de la Salut, University of Barcelona (UB), Barcelona, Spain
- A. Ginès
- Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Barcelona, Spain
- DOI
- https://doi.org/10.3389/fmolb.2023.1161893
- Journal volume & issue
-
Vol. 10
Abstract
Background: Integration of transcriptomic testing into EUS-FNA samples is a growing need for precision oncology in pancreatic ductal adenocarcinoma (PDAC). The NanoString platform is suitable for transcriptome profiling in low yield RNA samples.Methods: Inclusion of patients that underwent EUS-FNA cytological diagnosis of pancreatic ductal adenocarcinoma using 19G and/or 22G needles and subsequent surgical resection. Formalin-fixed, paraffin-embedded (FFPE) cytological and surgical samples underwent RNA extraction and transcriptomic analysis using a custom 52-gene NanoString panel of stromal PDAC features. Cell type abundance was quantified in FFPE specimens and correlated.Results: 18 PDAC patients were included. Mean EUS-FNA passes was 2 + 0.7. All FFPE passed the RNA quality control for genomic analysis. Hierarchical clustering on the global gene expression data showed that genes were differentially expressed between EUS and surgical samples. A more enriched cancer-associated fibroblasts and epithelial-mesenchymal transition transcriptomic profile was observed across surgical specimens whereas immunological biomarkers were more represented in EUS-FNA samples. Cytological examination confirmed a scanty representation of CAF and more immunological cell abundance in cytological samples in comparison to surgical specimens.Conclusion: Targeted transcriptomic NanoString profiling of PDAC samples obtained by EUS-FNA is a feasible approach for pre-surgical molecular analysis although stromal CAF/EMT mRNA biomarkers are underrepresented.
Keywords
